Status:

COMPLETED

Oral Nutritional Supplement Effect on HDL Function

Lead Sponsor:

Metagenics, Inc.

Conditions:

HDL

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)

Eligibility Criteria

Inclusion

  • Male and non-pregnant female patients or female patients of childbearing age on contraception age 18-80years.
  • Total HDL level 38mg/dL or lower in men and HDL 45 mg/dL or lower in women and a low HDL-P defined as less than 7000 by Spectracell LPP Plus.
  • CHL HDL Fx score equal to or greater than 0.9.
  • Patients will remain on their present diet, exercise program, medications (except for those who alter serum lipids) sleeping habits, alcohol intake, caffeine intake, smoking amount and emotional status as best as possible related to stress and anxiety and maintain body weight at baseline visit as best as possible to avoid confounding variables.
  • No other lipid lowering supplement can be taken during the study.
  • All lipid lowering supplements must have been discontinued at least 30 days prior t o study entry.

Exclusion

  • Pregnant females
  • Females of childbearing age not on an accepted contraception control method
  • Previous myocardial infarction within 5 years
  • Unstable angina
  • Previous stroke or TIA within 5 years
  • Uncompensated congestive heart failure
  • Previous PCTA or stent within 5 years
  • Previous CABG within 5 years
  • Patients on statins, fibrates, or other lipid lowering medications or any supplement known to affect serum lipids.
  • Known or previous cancer within 5 years
  • Type 1 diabetes mellitus
  • Kidney disease as defined by serum creatinine over 2.5 mg/dL

Key Trial Info

Start Date :

August 18 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2023

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT04529174

Start Date

August 18 2020

End Date

December 30 2023

Last Update

March 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hypertension Institute

Nashville, Tennessee, United States, 37205